Strategic Focus and Investment Logic for Pharma/CROs in Clinical Trial Digitalization
When it comes to the digitalization of clinical research, your first thought might be EDC or CTMS. Digital tools often seem to fall short of delivering their full potential. Faced with a plethora of digital products on the market, how should pharmaceutical companies and CROs choose the ones that truly fit their needs?
According to survey data from VCBeat, digitalization investments account for approximately 15% to 50% of the total costs in clinical research projects. Do enterprises truly need such high-cost digitalization investments? Given the numerous stages requiring digital support, implementing full-process digitalization at once would incur substantial costs. Therefore, prioritizing digitalization investments in specific stages based on project circumstances has become a key consideration for project managers.
What is the rationale behind budget allocation for the digitalization of clinical research by pharmaceutical companies and CROs? Which segment should be the primary focus of budget investment?
To address these questions,November 14, 2022, 20:00–21:30，VBSelectJoin HandsLinYanTong, jointly host an online live public lecture。This course will《What Should Be the Focus and Rationale for Pharmaceutical Companies/CROs in the Digitalization of Clinical Research?》as the theme, providing insights into budget allocation for the digitalization of clinical research by pharmaceutical companies or CROs.
Not only that, this session also invitesPan Yuanyuan, Vice President of R&D at Yingu PharmaceuticalsandWu Kai, Head of Clinical Operations in the Internal Medicine Therapeutic Area at Everest Medicines, join this issue's themed roundtable to discuss“How to Distinguish Between Genuine and Spurious Digitalization Needs Across Various Stages of Clinical Research?”, and“How can we assess the role of digitalization in reducing costs and improving efficiency across different stages of clinical trials?”and other topics.
For this live-streaming event, LinYanTong also providedSaaS-based EDC + CTMS: 50 free user slots across 3 projects。Scan the QR code in the poster below to register for the live stream.：
Key Point 1: The essence of digitalization is supply surplus;
Key Point 2: Two Key Aspects of Digitalization: Simulation-Based Digital Twins and Scenario-Driven Business Model Evolution;
Key Point 3: Divergent Logics Between Sponsors and Sites in Digital Clinical Trial Projects;
Key Point 4: The focus of digitalization for project owners: accumulation of operational data and decision-making guidance;
Key Point 5: Focus of Digitalization at Clinical Trial Sites: Enhancing Enrollment Efficiency and Optimizing Processes.
Founder of a Clinical Trial Sponsor or CRO Company
[Recommendation: ★★★★★]
Clinical Trial Sponsor or CRO Company Clinical Research Director
[Recommendation: ★★★★]
If you fall into any of the above categories, be sure not to miss this information-packed open lecture.
Founder of Linyantong Technology; Member of the Special Committee on Clinical Research Quality and Evaluation under the China Pharmaceutical Quality Association; Wuxi Taihu Leading Entrepreneurial Talent. With 18 years of experience in the pharmaceutical industry, he is dedicated to advancing the digitalization of clinical research, improving operational efficiency, and transforming the clinical research ecosystem. Previously employed at Rundo Pharma and the global CRO Clinipace, he possesses extensive expertise in ICH guidelines, international clinical operational requirements, and various pharmaceutical regulations governing clinical trials. He has participated in over 200 clinical research projects, including 15 Class 1 innovative drugs, 40 oncology products, 5 vaccine projects, and more than 50 global multi-center trials.
Vice President of R&D at Yingu Pharmaceutical Co., Ltd., with 14 years of experience in innovative drug development. Responsible for preclinical studies, clinical trials, regulatory submissions, and government affairs for drugs under development. Has overseen more than ten R&D projects for Class 1 and Class 2 new drugs, and has led the successful development, approval, and industrial commercialization of a Class 1.1 innovative drug. Possesses extensive expertise in R&D, management, and industrialization.
Head of Clinical Operations, Internal Medicine Therapeutic Area, Everest Medicines. Previously held positions at Bayer Schering, Novo Nordisk, Eli Lilly, AstraZeneca, and other pharmaceutical companies as well as CROs. With nearly 20 years of experience in clinical operations and project management, he/she has led teams responsible for the trial management of dozens of Phase I–III clinical trials at both national and global levels.
Linyantong (Tianjin) Technology Co., Ltd. is dedicated to providing digital and intelligent clinical research service solutions for the clinical research industry. The company currently serves as a Vice Chairman Unit of the CRO Branch of the China Pharmaceutical Quality Management Association, with a team of over 300 professionals covering 33 cities across China. The Linyantong Intelligent Clinical Research Monitoring Platform has obtained the Level 3 Classified Protection Certification from the Ministry of Public Security. To date, it has served more than 2,000 enterprise and hospital clients, with over 21,500 active online users. Currently, 219 projects are operational on the platform, achieving a 100% registration review approval rate. It has successfully facilitated the market launch of multiple products, including Benzenesulfonic Acid Anisotropium Bromide, Abdominal Aortic Endovascular Stent Grafts, Ambroxol Hydrochloride Solution for Inhalation, and Venlafaxine. Practical evidence demonstrates that Linyantong can help reduce clinical research budgets by more than 40%.
VCBeat Open Course
“Artery Open Course” is one of the branded columns under VCBeat’s “VCBeat Select.” Centered on addressing development pain points and exploring systemic solutions within the healthcare sector, it leverages an online live-streaming platform for knowledge sharing and exchange. By continuously inviting seasoned industry practitioners and experts to collaboratively develop a series of thematic courses, it aims to provide healthcare enterprises with in-depth, high-value, practical content. Artery Open Course: Making the selection of knowledge simpler.
Live Stream Reservation
Scan the QR code below to contact the assistant and schedule a live stream.
(If already added, please proactively contact the assistant)
